Experience with the treatment of Two Factor VIII Inhibitor Patients with Various Quantities of High-Dosage Factor VIII

E.		Scheibel
C.		Feddersen

E. Scheibel, Skovringen 19, 2950 Vedbaek (Denmark)

Two factor VIII inhibitor patients were selected for high-dosage factor VIII therapy due to progressive haemophilic arthropathy. During this treatment, they only received factor VIII preparations and no activated nor non-activated factor IX preparations.

The first patient was a known high responder. He received 180 units/kg/day of high-purity factor VIII (Factorate, Armour). The inhibitor first increased and then decreased below 1.0 BU/ml after 4 months and later below 0.3 BU/ml when the dose was reduced to 100 units/kg/day of factor VIII. However, the recovery and half-life of factor VIII remained abnormal.

The second patient was a low responder, previously with a maximum inhibitor level of 7.5 BU/ml. His pretreatment inhibitor

level was 2.2 BU/ml and the treatment was gradually reduced to two weekly doses of 20 units/kg (Kryobulin, Immuno of Kryo-precipitat, Nordic). Pretreatment recovery was abnormal, but recovery and half-life were normal after 2 weeks of treatment.

The continued treatment with factor VIII alone seems to have suppressed factor VIII antibody production and has possibly converted the high-responder patient to a low responder and cured the low-responder patient so that a normal factor VIII dose for prophylactic treatment suffices.